These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 27859453)

  • 41. Exploring the Obstacles to Implementing Economic Mechanisms to Stimulate Antibiotic Research and Development: A Multi-Actor and System-Level Analysis.
    Baraldi E; Ciabuschi F; Leach R; Morel CM; Waluszewski A
    Am J Law Med; 2016 May; 42(2-3):451-486. PubMed ID: 29086643
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
    Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
    Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Obstacles and perspectives of new antimicrobial concepts within research and development].
    Kloß F; Gerbach S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 May; 61(5):595-605. PubMed ID: 29594395
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe.
    Årdal C; Lacotte Y; Ploy MC
    Clin Infect Dis; 2020 Nov; 71(8):1994-1999. PubMed ID: 32060511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
    Kelly R; Zoubiane G; Walsh D; Ward R; Goossens H
    Lancet Infect Dis; 2016 Apr; 16(4):431-40. PubMed ID: 26708524
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others.
    Bettiol E; Hackett J; Harbarth S
    J Law Med Ethics; 2018 Jun; 46(1_suppl):5-8. PubMed ID: 30146955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reducing antimicrobial resistance through appropriate antibiotic usage in Singapore.
    Hsu LY; Kwa AL; Lye DC; Chlebicki MP; Tan TY; Ling ML; Wong SY; Goh LG
    Singapore Med J; 2008 Oct; 49(10):749-55. PubMed ID: 18946605
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving antibiotic markets for long-term sustainability.
    Kesselheim AS; Outterson K
    Yale J Health Policy Law Ethics; 2011; 11(1):101-67. PubMed ID: 21381513
    [No Abstract]   [Full Text] [Related]  

  • 50. Antimicrobial stewardship: bridging the gap between quality care and cost.
    Goff DA
    Curr Opin Infect Dis; 2011 Feb; 24 Suppl 1():S11-20. PubMed ID: 21200180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Promoting Antibacterial Drug Development: Select Policies and Challenges.
    Sertkaya A; Jessup A; Wong HH
    Appl Health Econ Health Policy; 2017 Feb; 15(1):113-118. PubMed ID: 27601239
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R; Green S
    J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibiotic discovery in the artificial intelligence era.
    Lluka T; Stokes JM
    Ann N Y Acad Sci; 2023 Jan; 1519(1):74-93. PubMed ID: 36447334
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics.
    Lum K; Bhatti T; Holland S; Guthrie M; Sassman S
    J Law Med Ethics; 2018 Jun; 46(1_suppl):66-74. PubMed ID: 30146960
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness and pricing of antibacterial drugs.
    Verhoef TI; Morris S
    Chem Biol Drug Des; 2015 Jan; 85(1):4-13. PubMed ID: 25521641
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel pre-clinical antibacterial pipeline database.
    Paulin S; Alm RA; Beyer P
    PLoS One; 2020; 15(7):e0236604. PubMed ID: 32722726
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The challenge of antimicrobial resistance: new regulatory tools to support product development.
    Tomayko JF; Rex JH; Tenero DM; Goldberger M; Eisenstein BI
    Clin Pharmacol Ther; 2014 Aug; 96(2):166-8. PubMed ID: 24823890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.
    Rex JH; Eisenstein BI; Alder J; Goldberger M; Meyer R; Dane A; Friedland I; Knirsch C; Sanhai WR; Tomayko J; Lancaster C; Jackson J
    Lancet Infect Dis; 2013 Mar; 13(3):269-75. PubMed ID: 23332713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antimicrobial innovation: a current update and perspective on the antibiotic drug development pipeline.
    Stephens LJ; Werrett MV; Sedgwick AC; Bull SD; Andrews PC
    Future Med Chem; 2020 Nov; 12(22):2035-2065. PubMed ID: 33169622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination drugs, an emerging option for antibacterial therapy.
    Cottarel G; Wierzbowski J
    Trends Biotechnol; 2007 Dec; 25(12):547-55. PubMed ID: 17997179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.